For a study, the researchers demonstrated that fecal microbiota transplantation (FMT) worsens the symptoms of inflammatory bowel disease (IBD). The researchers wanted to see if there was a risk of IBD activity worsening after FMT. MEDLINE (1946-June 2016), EMBASE (1954-June 2016), and the Cochrane Central Register of Controlled Trials were used to conduct an electronic search (2016). There were outlines in which FMT was given to IBD patients for IBD management or CDI (Clostridium difficile infection) treatment. The rate of deteriorating IBD activity was the primary endpoint. The researchers looked at 29 outcomes involving 514 FMT-treated IBD patients. The time between follow-ups ranged from 4 weeks to 3 years. The overall rate of IBD deterioration was 14.9% (95% CI:10–21%). I2 D 52.1%, Cochran Q test D 58.1, P D 0.01. Heterogeneity was discovered: I2 D 52.1%, Cochran Q test D 58.1, P D 0.01. Subgroup analyses were carried out a priori. Although not statistically significant, the pooled rate of deteriorating IBD activity after FMT for CDI (22.7% (95% CI: 13–36%) was higher than that after FMT for IBD (11.1% (95% CI: 7–17%). Lower GI FMT delivery was associated with a higher rate of deteriorating IBD activity (16.5% (95% CI: 11–24%)) than upper GI FMT delivery (5.6% (95% CI: 2–16%). In high-quality research and randomized controlled trials (RCTs), deterioration rates revealed a marginal risk of worsening IBD activity (4.6%, 95% CI:1.8–11%). In high-quality RCTs, rates of IBD declining were only modest.
Link:www.tandfonline.com/doi/full/10.1080/19490976.2017.1353848
